香雪製藥(300147.SZ):TCR-T新藥研發項目在美國獲得藥物臨牀試驗許可
格隆匯 9 月 23日丨香雪製藥(300147.SZ)公佈,控股子公司廣東香雪精準醫療技術有限公司(以下簡稱“香雪精準”)於2018年7月與ATHENEX,INC.(以下簡稱“Athenex”)簽署了《股份認購協議》、《股東協議》,與AxisTherapeuticsLimited(以下簡稱“Axis”,為香雪精準與Athenex合資成立)簽署了《授權協議》。香雪精準及其關聯方將擁有的針對NY-ESO-1陽性表達的TCR-T細胞治療技術授予Axis在中華人民共和國(不含港澳台地區)以外的國家和地區以獨佔許可的方式使用知識產權,以開發和商業化許可產品和技術。具體內容詳見巨潮資訊網(www.cninfo.com.cn)《關於子公司簽署授權協議及相關事項的公告》(公告編號:2018—047)。
近日,公司接到Athenex通知,美國食品和藥物管理局(FDA)批准了TCRT-ESO-A2的新藥臨牀試驗申請(IND),該新藥可以進入臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.